Topic Editors

Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, 41124 Modena, Italy
DermoLAB, Department of Surgical, Medical, Dental and Morphological Science, University of Modena and Reggio Emilia, 41124 Modena, Italy

Skin Barrier Function and Immune Mediators as Key Therapeutic Targets of Main Inflammatory Diseases

Abstract submission deadline
30 June 2026
Manuscript submission deadline
31 August 2026
Viewed by
733

Topic Information

Dear Colleagues,

Inflammation usually refers to the defensive response of living tissue to inflammatory factors and local damage. The skin, as one of the largest immune organs, is involved in many inflammatory conditions, such as psoriasis, atopic dermatitis, acne, bullous diseases, and hidradenitis suppurativa. These conditions are closely related to severe systemic complications, such as arteriosclerosis, cardiovascular disease, abnormal fat metabolism, nephrosclerosis, and systemic amyloidosis. Timely diagnosis and precision medicine are particularly important for patients, and thus, continued research efforts are required. The following Topic encourages contributors to explore the biological and clinical aspects of the complex interplay between the skin barrier and inflammation, which may act as pivotal actors in the pathogenesis of many diseases. We hope to shed new light on this exciting and insightful field of research from a multidisciplinary perspective. A better understanding of the corresponding pathogenetic mechanisms can aid in the development of new therapeutic agents aimed at eradicating these diseases. We welcome original research papers in addition to critiques and opinion papers. Special clinical cases may also be included. As a part of this Topic, the readership will find accounts of relevant research carried out by numerous healthcare professionals and researchers with extensive knowledge in basic and clinical settings, with the aim of translating basic research into clinical practice.

Dr. Marco Manfredini
Dr. Carlo Pincelli
Topic Editors

Keywords

  • atopic dermatitis
  • prurigo nodularis
  • psoriasis
  • immunology
  • biologics

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cells
cells
5.2 10.5 2012 16 Days CHF 2700 Submit
Immuno
immuno
2.5 3.7 2021 31.6 Days CHF 1200 Submit
International Journal of Molecular Sciences
ijms
4.9 9.0 2000 20.5 Days CHF 2900 Submit
Journal of Clinical Medicine
jcm
2.9 5.2 2012 17.7 Days CHF 2600 Submit
Allergies
allergies
- - 2021 34.8 Days CHF 1000 Submit
Dermato
dermato
- - 2021 25.1 Days CHF 1000 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
22 pages, 1794 KiB  
Review
Chronic Rhinosinusitis with Nasal Polyps: Window of Immunologic Responses and Horizon of Biological Therapies
by Simin Farokhi, Seyed Mehdi Tabaie, Arshia Fakouri, Shirin Manshouri, Nikoo Emtiazi, Ayda Sanaei, Mohammad Mahjoor, Amir Mohammad Akbari, Ali Daneshvar and Farhad Seif
Immuno 2025, 5(3), 26; https://doi.org/10.3390/immuno5030026 - 11 Jul 2025
Viewed by 430
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifaceted inflammatory disorder characterized by distinct immunopathogenic entities, including type 2 inflammation mediated by cytokines such as interleukin-4 (IL-4), IL-5, and IL-13. These cytokines contribute to eosinophilic inflammation, epithelial barrier dysfunction, and mucus overproduction, resulting [...] Read more.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifaceted inflammatory disorder characterized by distinct immunopathogenic entities, including type 2 inflammation mediated by cytokines such as interleukin-4 (IL-4), IL-5, and IL-13. These cytokines contribute to eosinophilic inflammation, epithelial barrier dysfunction, and mucus overproduction, resulting in polyp formation. Advances in molecular understanding have resulted in the identification of CRSwNP endotypes, suggesting personalized treatment approaches. Conventional therapies, such as intranasal and systemic corticosteroids, provide symptom relief but are restricted by side effects and polyp recurrence, necessitating the development of novel targeted approaches. Biologic therapies represent a breakthrough in CRSwNP management. Monoclonal antibodies such as dupilumab, omalizumab, mepolizumab, and Benralizumab (IL-5 receptor alpha) target key mediators of type 2 inflammation, leading to substantial improvements in polyp size, symptom control, and quality of life. Additionally, emerging therapies like tezepelumab and brodalumab aim to address broader immune mechanisms, including type 1 and type 3 inflammation. These advancements enable tailored treatment approaches that optimize outcomes and reduce reliance on surgical interventions. Biomarker-driven research continues to refine CRSwNP classification and treatment efficacy, emphasizing precision medicine. Future efforts should focus on expanding the therapeutic landscape, investigating long-term impacts of biologics, and exploring their combinatory potential to improve disease control. This review discusses the role of innate and adaptive immunity in the pathogenesis of CRSwNP and suggests novel cytokine-targeted strategies for further considering personalized medicine in future therapeutic plans. Full article
Show Figures

Figure 1

Back to TopTop